Cytoreductive Surgery And HIPEC For Peritoneal Carcinomatosis Of A Gallbladder Carcinoma | 40554
Journal of Cancer Science & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Introduction: The prognosis of gallbladder carcinoma is extremely poor as tumors usually do not show any symptoms until
they have become advanced. As a result, in most cases the tumor cannot be removed by surgery completely. The five-year
survival rate of patients is approximately 6-7%. After diagnosis the median survival time is approximately four to five months.
If the carcinoma is removed completely, the five-year survival rate will increase to 10-60%.
Methods: One female patient with gallbladder carcinoma who had a primary R1 resection of the gallbladder, partial liver
tissue as well as the Whipple procedure, developed a small bowel ileus after three months. This occured due to a large nodular
peritoneal carcinomatosis without evidence of extra peritoneal metastasis. A primary cytoreductive surgery was performed
followed by HIPEC.
Results: The intra- and postoperative progress was uncomplicated with primary wound healing. The patient received an
additive systematic chemotherapy after the completion of her rehabilitation. The current staging shows no evidence of recarcinomatosis
Conclusion: The HIPEC is a modern technique which can be used especially for patients with metastatic cancer. In the current
literature there can be hardly found any information on the practice of HIPEC in patients with metastatic gallbladder or bile
duct carcinoma. An accurate selection of a potential patient plays a key role.